Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.54 |
| ▸ | USP2 | O75604 | 1/20 | 0.54 |
| ▸ | CTSK | P43235 | 4/20 | 0.54 |
| ▸ | CTSL | P07711 | 3/20 | 0.48 |
| ▸ | CTSB | P07858 | 3/20 | 0.48 |
| ▸ | CTSD | P07339 | 1/20 | 0.47 |
| ▸ | CTSS | P25774 | 1/20 | 0.47 |
| ▸ | PKM | P14618 | 1/20 | 0.46 |
| ▸ | RECQL | P46063 | 1/20 | 0.44 |
| ▸ | HRH2 | P25021 | 2/20 | 0.43 |
| ▸ | HRH1 | P35367 | 2/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | PREP | P48147 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | CA1 | P00915 | 1/20 | 0.41 |
| ▸ | CA2 | P00918 | 1/20 | 0.41 |
| ▸ | CA7 | P43166 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5451145 | 1.00 | SMN1; SMN2 (0.54) | SMN1; SMN2USP2CTSKCTSLCTSB | |
| SCHEMBL5441244 | 1.00 | SMN1; SMN2 (0.54) | SMN1; SMN2USP2CTSKCTSLCTSB | |
| SCHEMBL23050302 | 0.87 | CTSK (0.53) | SMN1; SMN2USP2CTSKCTSLCTSB | |
| SCHEMBL23590380 | 0.87 | CTSK (0.51) | SMN1; SMN2USP2CTSKCTSLCTSB | |
| SCHEMBL15947741 | 0.85 | CTSK (0.50) | SMN1; SMN2USP2CTSKCTSLCTSB | |
| SCHEMBL13287349 | 0.85 | CTSK (0.50) | CTSKCTSLCTSBHRH2HRH1 | |
| SCHEMBL23845173 | 0.85 | CTSK (0.50) | CTSKCTSLCTSBHRH2HRH1 | |
| SCHEMBL5416784 | 0.85 | CTSK (0.50) | CTSKCTSLCTSBHRH2HRH1 | |
| SCHEMBL5435526 | 0.84 | CTSK (0.49) | CTSKCTSLCTSBHRH2HRH1 | |
| SCHEMBL5451133 | 0.84 | CTSK (0.49) | CTSKCTSLCTSBHRH2HRH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117567338-A | Novel heteroaryl triazole compounds as pesticides | 拜耳公司 | 2024-02-20 | — | — | CN | disclosed |
| US-20190231787-A1 | METHODS AND COMPOUNDS FOR TREATING ALCOHOL USE DISORDERS AND ASSOCIATED DISEASES | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2019-08-01 | — | — | US | disclosed |
| US-9464066-B2 | Deuterated compounds useful for treating neurodegenerative diseases | PHARMATROPHIX, INC. (US) | 2016-10-11 | — | — | US | disclosed |
| US-9464066-B2 | Deuterated compounds useful for treating neurodegenerative diseases | PHARMATROPHIX, INC. (US) | 2016-10-11 | — | — | US | disclosed |
| US-20160229823-A1 | DEUTERATED COMPOUNDS USEFUL FOR TREATING NEURODEGENERATIVE DISEASES | Ricerca Biosciences, LLC | 2016-08-11 | — | — | US | disclosed |
| US-20160229823-A1 | DEUTERATED COMPOUNDS USEFUL FOR TREATING NEURODEGENERATIVE DISEASES | Ricerca Biosciences, LLC | 2016-08-11 | — | — | US | disclosed |
| US-20120322799-A1 | DEUTERATED COMPOUNDS USEFUL FOR TREATING NEURODEGENERATIVE DISEASES | PHARMATROPHIX, INC. (US) | 2012-12-20 | — | — | US | disclosed |
| US-20110230479-A1 | NEUROTROPHIN MIMETICS AND USES THEREOF | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2011-09-22 | — | — | US | disclosed |
| WO-2010102212-A2 | NEUROTROPHIN MIMETICS AND USES THEREOF | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 2010-09-10 | — | — | WO | disclosed |
| EP-1134213-B1 | Process for the preparation of substituted N-(indole-2-carbonyl)- glycinamides | PFIZER (US) | 2005-11-02 | — | — | EP | disclosed |
| EP-0832065-B1 | SUBSTITUTED N-(INDOLE-2-CARBONYL)-GLYCINAMIDES AND DERIVATIVES AS GLYCOGEN PHOSPHORYLASE INHIBITORS | PFIZER (US) | 2001-10-10 | — | — | EP | disclosed |
| EP-1134213-A2 | Process for the preparation of substituted N-(indole-2-carbonyl)- glycinamides | PFIZER INC. (US) | 2001-09-19 | — | — | EP | disclosed |
| US-6277877-B1 | GLYCOGEN PHOSPHORYLASE INHIBITOR; ANTIDIABETIC AGENTS | PFIZER, INC. | 2001-08-21 | — | — | US | disclosed |
| US-6107329-A | HYPOTENSIVE AGENTS; CARDIOVASCULAR DISORDERS | PFIZER, INC. (US) | 2000-08-22 | — | — | US | disclosed |
| EP-0832065-A1 | SUBSTITUTED N-(INDOLE-2-CARBONYL)-GLYCINAMIDES AND DERIVATIVES AS GLYCOGEN PHOSPHORYLASE INHIBITORS | PFIZER INC. (US) | 1998-04-01 | — | — | EP | disclosed |
| WO-1996039384-A1 | SUBSTITUTED N-(INDOLE-2-CARBONYL)-GLYCINAMIDES AND DERIVATIVES AS GLYCOGEN PHOSPHORYLASE INHIBITORS | PFIZER, INC. (US) | 1996-12-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160229823-A1 | DEUTERATED COMPOUNDS USEFUL FOR TREATING NEURODEGENERATIVE DISEASES | NLN, NGF, BDNF | SMN1; SMN2 10/4885USP2 2291/4885CTSK 1045/4885 |
| US-20120322799-A1 | DEUTERATED COMPOUNDS USEFUL FOR TREATING NEURODEGENERATIVE DISEASES | NLN, NGF, BDNF | SMN1; SMN2 10/4885USP2 2291/4885CTSK 1045/4885 |
| US-20190231787-A1 | METHODS AND COMPOUNDS FOR TREATING ALCOHOL USE DISORDERS AND ASSOCIATED DISEASES | ADH1A, NTRK2, ADH1C | SMN1; SMN2 1441/4885USP2 2823/4885CTSK 3353/4885 |
| US-20110230479-A1 | NEUROTROPHIN MIMETICS AND USES THEREOF | BDNF, NTRK2, NGF | SMN1; SMN2 24/4885USP2 2065/4885CTSK 1101/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.